Alpha Cognition Inc. (NASDAQ: ACOG) concluded fiscal year 2025 with its ZUNVEYL treatment demonstrating increasingly durable traction in long-term care facilities, according to an updated coverage report from Stonegate Capital Partners. The company reported fourth quarter net product revenue of $2.5 million, bringing total fiscal year revenue to $10.2 million, which included $6.8 million in ZUNVEYL sales. These financial indicators suggest the treatment is gaining meaningful commercial acceptance in a challenging healthcare market.
Demand metrics showed significant acceleration during the quarter, with bottles dispensed rising 62% quarter-over-quarter to 4,941 units. December alone reached a record 1,859 bottles, indicating strong momentum heading into the new year. The company's management believes these figures demonstrate that ZUNVEYL is moving beyond early trial use and becoming more embedded in facility treatment protocols, a critical milestone for any new pharmaceutical product.
Repeat ordering behavior provides further evidence of ZUNVEYL's integration into standard care practices. The company reported 729 ordering homes, with 82% placing repeat orders, and 865 prescribers, with 69% writing repeat prescriptions. This pattern of sustained usage suggests healthcare providers are finding clinical value in the treatment rather than simply testing it on a limited basis. The consistency of reorders supports the company's assertion that ZUNVEYL is establishing itself as a regular component of long-term care treatment regimens.
Alpha Cognition appears financially positioned to continue its commercialization efforts, ending fiscal year 2025 with $66.0 million in cash, which provides runway into 2027 according to company projections. This financial stability allows the company to focus on scaling operations without immediate fundraising concerns. Management expects continued sequential sales growth throughout 2026, suggesting confidence in the product's ongoing market acceptance.
The company's progress represents an important development in the treatment landscape for conditions addressed by ZUNVEYL, though specific indications were not detailed in the coverage update. Successful commercialization in long-term care settings often requires navigating complex regulatory environments and establishing trust with healthcare providers who manage vulnerable patient populations. The reported metrics suggest Alpha Cognition is making meaningful progress on both fronts, potentially creating a foundation for broader market expansion in the future. For more information about the company, visit https://www.alphacognition.com.
